|
09 Jul 2021 |
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
|
|
09 Jul 2021 |
Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organisation (ECCO)
|
|
09 Jul 2021 |
Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases
|
|
09 Jul 2021 |
Bacainn Therapeutics Presents at ECCO ‘21 Results from Phase 1 Study that Shows BT051, an Oral, Locally-Acting Inhibitor of Neutrophil Trafficking and Activity, Is Safe and Well-Tolerated in Healthy Adults
|
|
07 Jul 2021 |
Pathios Therapeutics Presents Preclinical In Vivo Proof of Concept Data for small molecule GPR65 inhibitor in human PDX cancer model
|
|
07 Jul 2021 |
Eisbach Bio receives EUR 8 million government grant to progress COVID-19 antiviral through Phase I/II clinical development
|
|
07 Jul 2021 |
UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
|
|
06 Jul 2021 |
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD
|
|
06 Jul 2021 |
Almirall and MC2 Therapeutics announce completion of decentralized procedure in Europe for the topical treatment of mild to moderate psoriasis vulgaris in adults
|
|
06 Jul 2021 |
HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China
|
|
02 Jul 2021 |
Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens
|
|
02 Jul 2021 |
Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
|
|
02 Jul 2021 |
LG Chem Announces Topline Results of LC350189 From the Phase 2 Study (CLUE Study) Promising to Be a New Treatment Alternative With Improved Efficacy and Safety Profiles for Chronic Gout Patients
|
|
02 Jul 2021 |
Ildong Pharmaceutical starts Phase 1 study of new diabetes therapy in Germany
|
|
02 Jul 2021 |
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
|
|
01 Jul 2021 |
Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene
|
|
01 Jul 2021 |
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
|
|
01 Jul 2021 |
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
|
|
01 Jul 2021 |
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
|
|
01 Jul 2021 |
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease
|
|
01 Jul 2021 |
Saniona Initiates Phase 1 Clinical Trial of SAN711
|
|
01 Jul 2021 |
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670
|
|
01 Jul 2021 |
Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis
|
|
01 Jul 2021 |
Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia
|
|
29 Jun 2021 |
Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection
|
